{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:02:25Z","timestamp":1771066945432,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T00:00:00Z","timestamp":1402444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00432-014-1734-z","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T19:30:41Z","timestamp":1402428641000},"page":"1705-1713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["YM155 reverses rapamycin resistance in renal cancer by decreasing survivin"],"prefix":"10.1007","volume":"140","author":[{"given":"Hidekazu","family":"Koike","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsunari","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,11]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","volume":"22","author":"DC Altieri","year":"2003","unstructured":"Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581\u20138589","journal-title":"Oncogene"},{"key":"1734_CR2","first-page":"1327","volume":"79","author":"DC Altieri","year":"1999","unstructured":"Altieri DC, Marchisio PC (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327\u20131333","journal-title":"Lab Invest"},{"key":"1734_CR3","first-page":"89","volume":"37","author":"H Asechi","year":"2010","unstructured":"Asechi H, Hatano E, Nitta T et al (2010) Resistance to cisplatin-induced apoptosis via PI3\u00a0K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 37:89\u201396","journal-title":"Int J Oncol"},{"key":"1734_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6:17\u201327 (Review)","journal-title":"Target Oncol"},{"key":"1734_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1476-5586(04)80051-4","volume":"6","author":"A Chandele","year":"2004","unstructured":"Chandele A, Prasad V, Jagtap JC et al (2004) Upregulation of survivin in G2\/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6:29\u201340","journal-title":"Neoplasia"},{"key":"1734_CR6","first-page":"179","volume":"3","author":"Q Cheng","year":"2012","unstructured":"Cheng Q, Ling X, Haller A et al (2012) Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3:179\u2013197","journal-title":"Int J Biochem Mol Biol"},{"key":"1734_CR7","first-page":"2377","volume":"22","author":"Y Dong","year":"2002","unstructured":"Dong Y, Sui L, Watanabe Y et al (2002) Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 22:2377\u20132383","journal-title":"Anticancer Res"},{"key":"1734_CR8","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1074\/jbc.M606203200","volume":"282","author":"PO Est\u00e8ve","year":"2007","unstructured":"Est\u00e8ve PO, Chin HG, Pradhan S (2007) Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282:2615\u20132625","journal-title":"J Biol Chem"},{"key":"1734_CR9","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","volume":"27","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Zatloukal P, Roubec J et al (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27:4481\u20134486","journal-title":"J Clin Oncol"},{"key":"1734_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6605713","volume":"103","author":"T Iwasa","year":"2010","unstructured":"Iwasa T, Okamoto I, Takezawa K et al (2010) Marked anti-tumour activity of the combination of YM155, a novel surviving suppressant, and platinum-based drugs. Br J Cancer 103:36\u201342","journal-title":"Br J Cancer"},{"key":"1734_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.leukres.2010.11.016","volume":"35","author":"A Kita","year":"2011","unstructured":"Kita A, Nakahara T, Yamanaka K et al (2011) Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 35:787\u2013792","journal-title":"Leuk Res"},{"key":"1734_CR12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.juro.2010.12.005","volume":"185","author":"H Koike","year":"2011","unstructured":"Koike H, Morikawa Y, Sekine Y et al (2011) Survivin is associated with cell proliferation and has a role in 1a, 25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. J Urol 185:1497\u20131503","journal-title":"J Urol"},{"key":"1734_CR13","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","volume":"11","author":"B Kumar","year":"2012","unstructured":"Kumar B, Yadav A, Lang JC et al (2012) YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther 11:1988\u20131998","journal-title":"Mol Cancer Ther"},{"key":"1734_CR14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10637-009-9333-6","volume":"29","author":"KD Lewis","year":"2011","unstructured":"Lewis KD, Samlowski W, Ward J et al (2011) A multi-center phase II evaluation of the small molecule surviving suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29:161\u2013166","journal-title":"Invest New Drugs"},{"key":"1734_CR15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","volume":"60","author":"B Ljungberg","year":"2011","unstructured":"Ljungberg B, Campbell SC, Choi HY et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60:615\u2013621","journal-title":"Eur Urol"},{"key":"1734_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","volume":"16","author":"D Mahalingam","year":"2010","unstructured":"Mahalingam D, Medina EC, Esquivel JA 2nd et al (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16:141\u2013153","journal-title":"Clin Cancer Res"},{"key":"1734_CR17","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/emboj\/cdg263","volume":"22","author":"H Marusawa","year":"2003","unstructured":"Marusawa H, Matsuzawa S, Welsh K et al (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22:2729\u20132740","journal-title":"EMBO J"},{"key":"1734_CR18","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita AC, Mita MM, Nawrocki ST et al (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14:5000\u20135005","journal-title":"Clin Cancer Res"},{"key":"1734_CR19","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.1999.17.7.2100","volume":"17","author":"M Monz\u00f3","year":"1999","unstructured":"Monz\u00f3 M, Rosell R, Felip E et al (1999) A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol 17:2100\u20132104","journal-title":"J Clin Oncol"},{"key":"1734_CR20","doi-asserted-by":"crossref","first-page":"e28841","DOI":"10.1371\/journal.pone.0028841","volume":"6","author":"F Morgillo","year":"2011","unstructured":"Morgillo F, Martinelli E, Troiani T et al (2011) Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS ONE 6:e28841","journal-title":"PLoS ONE"},{"key":"1734_CR21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbrc.2012.02.089","volume":"419","author":"Y Morikawa","year":"2012","unstructured":"Morikawa Y, Koike H, Sekine Y et al (2012) Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem Biophys Res Commun 419:584\u2013589","journal-title":"Biochem Biophys Res Commun"},{"key":"1734_CR22","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601\u20135608","journal-title":"J Clin Oncol"},{"key":"1734_CR23","doi-asserted-by":"crossref","first-page":"e38625","DOI":"10.1371\/journal.pone.0038625","volume":"7","author":"YS Na","year":"2012","unstructured":"Na YS, Yang SJ, Kim SM et al (2012) YM155 induces EGFR suppression in pancreatic cancer cells. PLoS ONE 7:e38625","journal-title":"PLoS ONE"},{"key":"1734_CR24","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","volume":"67","author":"T Nakahara","year":"2007","unstructured":"Nakahara T, Kita A, Yamanaka K et al (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone refractory prostate tumor xenografts. Cancer Res 67:8014\u20138021","journal-title":"Cancer Res"},{"key":"1734_CR25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CAD.0b013e328344ac68","volume":"22","author":"T Nakahara","year":"2011","unstructured":"Nakahara T, Yamanaka K, Hatakeyama S et al (2011a) YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22:454\u2013462","journal-title":"Anticancer Drugs"},{"key":"1734_CR26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","volume":"102","author":"T Nakahara","year":"2011","unstructured":"Nakahara T, Kita A, Yamanaka K et al (2011b) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102:614\u2013621","journal-title":"Cancer Sci"},{"key":"1734_CR27","doi-asserted-by":"crossref","first-page":"25903","DOI":"10.1074\/jbc.M603414200","volume":"281","author":"XH Peng","year":"2006","unstructured":"Peng XH, Karna P, Cao Z et al (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281:25903\u201325914","journal-title":"J Biol Chem"},{"key":"1734_CR28","first-page":"202","volume":"1845","author":"A Rauch","year":"2014","unstructured":"Rauch A, Hennig D, Sch\u00e4fer C et al (2014) Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta 1845:202\u2013220","journal-title":"Biochim Biophys Acta"},{"key":"1734_CR29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3816\/CGC.2005.n.029","volume":"4","author":"BI Rini","year":"2005","unstructured":"Rini BI (2005) SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer 4:175\u2013180","journal-title":"Clin Genitourin Cancer"},{"key":"1734_CR30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","volume":"35","author":"BM Ryan","year":"2009","unstructured":"Ryan BM, O\u2019Donovan N, Duffy MJ et al (2009) Survivin: a new target for anticancer therapy. Cancer Treat Rev 35:553\u2013562","journal-title":"Cancer Treat Rev"},{"key":"1734_CR31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/gut.46.5.645","volume":"46","author":"AI Sarela","year":"2000","unstructured":"Sarela AI, Macadam RC, Farmery SM et al (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645\u2013650","journal-title":"Gut"},{"key":"1734_CR32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3835(02)00190-8","volume":"184","author":"N Takai","year":"2002","unstructured":"Takai N, Miyazaki T, Nishida M et al (2002) Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 184:105\u2013116","journal-title":"Cancer Lett"},{"key":"1734_CR33","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/0008-5472.CAN-05-3248","volume":"66","author":"E Tirr\u00f2","year":"2006","unstructured":"Tirr\u00f2 E, Consoli ML, Massimino M et al (2006) Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 66:4263\u20134272","journal-title":"Cancer Res"},{"key":"1734_CR34","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","volume":"17","author":"K Yamanaka","year":"2011","unstructured":"Yamanaka K, Nakahara T, Yamauchi T et al (2011) Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 17:5423\u20135431","journal-title":"Clin Cancer Res"},{"key":"1734_CR35","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","volume":"59","author":"N Zaffaroni","year":"2002","unstructured":"Zaffaroni N, Pennati M, Colella G et al (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406\u20131412","journal-title":"Cell Mol Life Sci"},{"key":"1734_CR36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1582-4934.2005.tb00361.x","volume":"9","author":"N Zaffaroni","year":"2005","unstructured":"Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. J Cell Mol Med 9:360\u2013372","journal-title":"J Cell Mol Med"},{"key":"1734_CR37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbrc.2010.03.165","volume":"395","author":"P Zhao","year":"2010","unstructured":"Zhao P, Meng Q, Liu LZ et al (2010) Regulation of survivin by PI3\u00a0K\/Akt\/p70S6K1 pathway. Biochem Biophys Res Commun 395:219\u2013224","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1734-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-014-1734-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1734-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T08:01:29Z","timestamp":1565510489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-014-1734-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,11]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s00432-014-1734-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,11]]}}}